HIV :: Surprising attitudes towards HIV vaccine research
A survey of U.S. adults has found that a majority believe that HIV vaccines are the best hope for controlling the global AIDS epidemic and are confident such vaccines can be made.
HIV
HIV :: Confusion and Conflict when it comes to HIV and AIDS
In Canada, HIV was first diagnosed among gay men. Later, hemophiliacs and others with health problems were infected due to tainted blood received through blood transfusions. People infected early on had no treatment available! A new and strange virus was weakening the immune system and causing illness in various ways, (what we now know as opportunistic. infections). That?s all we knew! Those who were infected looked for ways to boost their immune system. Not everyone affected by the disease was dying. Unfortunately, the media wrote only about those who were being ravaged by the disease and dying.
HIV :: HIV Therapy Greatly Extends Life of Key T Cells
Interleukin-2 (IL-2), an immune-boosting drug used experimentally in HIV therapy, greatly increases the lifespan of certain subsets of immune system T cells in some HIV-positive people who respond to this therapy, discovered researchers from the National Institutes of Health (NIH) Clinical Center and the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. A report describing the study, led by the Clinical Center?s Joseph A. Kovacs, M.D., appears online today in The Journal of Clinical Investigation.
HIV :: Fixed dose combination drug product lamivudine and zidovudine tablets
The Food and Drug Administration within the U.S. Department of Health and Human Services (HHS/FDA) announced the tentative approval of the fixed-dose combination drug product lamivudine and zidovudine tablets manufactured by Aurobindo Pharma Ltd. of Hyderabad, India.
HIV :: Silicon Reverses Facial Wasting in AIDS Patients
AIDS patients with a disfiguring skin complication caused by HIV infection can be treated safely and successfully with applications of an inexpensive silicone oil preparation, according to research reported in Dermatologic Surgery, the medical journal of the American Society for Dermatologic Surgery (ASDS).
HIV :: First Generic Nevirapine for AIDS Relief
The Food and Drug Administration (FDA) announced the tentative approval of two applications for nevirapine tablets manufactured by Ranbaxy Laboratories Limited, Guragon, India and Aurobindo Pharma Limited, Hyderabad, India. These are the first generic versions of Viramune Tablets manufactured by Boehringer Ingelheim. These products will now be available for consideration for purchase under the President?s Emergency Plan for AIDS Relief (PEPFAR).
HIV :: Efavirenz for AIDS Relief
The Food and Drug Administration (FDA) within the U.S. Department of Health and Human Services (HHS) announced the tentative approval of efavirenz tablets manufactured by Aurobindo Pharma LTD. of Hyderabad, India. This product is the first tentatively approved generic version of Sustiva Tablets (manufactured by Bristol-Myers Squibb). Efavirnez will now be available for consideration for purchase under the President’s Emergency Plan for AIDS Relief (PEPFAR).
HIV :: Aptivus – New Therapy for HIV Patients with Advanced Disease
The Food and Drug Administration (FDA) announced the approval of Aptivus (tipranavir) capsules, an HIV protease inhibitor, to be given with ritonavir for treatment of HIV-1 infected adults. This is the second drug approved for patients with advanced HIV disease, and provides a new therapy for patients with limited treatment options.
HIV :: Lamivudine – Generic AIDS Drug for AIDS Relief
The Food and Drug Administration (FDA) announced the tentative approval of Lamivudine Tablets manufactured by Aurobindo Pharma LTD. Hyderabad, India. This product will now be available for consideration for purchase under the President?s Emergency Plan for AIDS Relief (PEPFAR).
HIV :: Glaxo inks AIDS vaccine deal with non-profit group
GlaxoSmithKline Plc is to develop an experimental AIDS vaccine in collaboration with a non-profit group, in the first such public-private HIV vaccine partnership involving a major company.